Adenoviruses (AdV) have emerged as important causes of morbidity and mortality in patients after hematopoietic SCT (HSCT). Early diagnosis of the infection by detection of viral DNA may improve the prognosis. A surveillance strategy was evaluated for detection of AdV DNA by PCR in a prospective study of unselected allogeneic HSCT recipients. In parallel with a routine CMV surveillance program, plasma from 20 children and 77 adults was analyzed by quantitative PCR for detection of AdV DNA. In addition, in 12 unselected patients, the presence of AdV-specific T cells were analyzed by enzyme-linked immunosorbent spot (ELISPOT) at 1 to 3 months after transplantation. A total of 5 of 97 (5%) patients had detectable AdV DNA in peripheral blood. Only one patient had high titers and none developed AdV disease. BM as a source of stem cells and myelodysplastic syndrome as the indication for transplantation were independently associated with higher risk of acquiring AdV infection. AdV-specific T cells were detected in 7 (58%) of 12 patients. Although AdV DNA was found in peripheral blood by quantitative PCR in 5% of patients undergoing allogeneic HSCT, the present surveillance program did not have a significant effect on the clinical outcome.
Introduction
The number of patients undergoing allogeneic hematopoietic SCT (HSCT) is steadily increasing, and with patients in an immunocompromised state after transplantation, the outcome of this intervention is largely dependent on how well complications in the form of severe infections can be adequately diagnosed and controlled. Illustrative of this is the dramatic decrease in mortality from CMV complications that has been achieved by the introduction of routine surveillance for this virus, and prompt introduction of effective antiviral regimes.
Adenovirus (AdV) infections have been reported at incidences varying from a few to as much as 47% in recipients of HSCT and may be associated with high morbidity and mortality. It has especially emerged as a significant pathogen in children undergoing high-risk allogeneic HSCT procedures such as transplants from haploidentical donors. Some AdV infections may be asymptomatic, but the clinical manifestations vary with serotypes. The most feared sequelae in immunocompromised individuals include enteritis, hemorrhagic cystitis, nephritis, fulminant hepatitis and disseminated disease; the mortality rate can be as great as 80%. [1] [2] [3] [4] [5] [6] [7] [8] The risk of disseminated disease has been shown to correlate positively with viral load as measured by quantitative PCR methods. [9] [10] [11] Cidofovir has emerged as the primary therapy for AdV infection. The drug was recently evaluated in a highrisk pediatric population and was found to be safe and mostly well tolerated. 12 Rather commonly, immunosuppressive treatment has been reduced, as reconstitution of the lymphocytic immune system is associated with viral clearance. [13] [14] [15] AdV-specific T cells have been detected in children after HSCT and seem to protect against AdV disease. 16 For this reason, immunotherapy with donor T cells has been suggested, and a novel approach using purified AdV-specific donor T cells is promising, although in need of further evaluation. 17 At present, surveillance of AdV infection after HSCT is not routinely implemented, although the technology of choice, quantitative PCR, is widely available. The possible advantages are that such surveillance programs facilitate early detection and intervention and promote preemptive treatment before symptoms emerge. Cidofovir preemptively administered for AdV infection seems to be more effective than treatment later in the course of disease. 18 However, before a robust and comprehensive surveillance program can be implemented, definitive evidence must be available based on proven intervention for patients who are virus positive, and such programs must balance effects and costs. The current study is an attempt to evaluate the clinical benefit of a surveillance program for AdV in HSCT patients, designed to be feasible and easily administered in the clinical setting. Furthermore, a portion of the patients was examined regarding the presence of AdV-specific T cells.
Materials and methods
Study population, collection of samples and extraction of clinical data During an 18-month period (March 2006 to September 2007), patients with a hematological diagnosis that warranted allogeneic HSCT at two major Swedish transplantation centers (Sahlgrenska University Hospital, Gothenburg and Karolinska University Hospital, Stockholm) were asked to participate in the study. Adults as well as children, after giving their (or their guardians') informed consent, were eligible for enrollment. The study was approved by the regional ethical review board in Stockholm. Peripheral blood samples, in parallel with the routine CMV surveillance, were collected weekly during the first 9 weeks after HSCT and at follow-up visits at approximately 3, 6 and 12 months later.
Clinical data were extracted from the medical records, and results from additional sampling for detection of AdV DNA in blood as part of the clinical routine were also recorded. Furthermore, results regarding AdV analysis in other body fluids than peripheral blood were extracted from the medical record. Patients who survived for the entire follow-up period but provided o5 blood samples for AdV detection were considered noncompliant with the surveillance protocol and excluded (a total of 4 out of 101 patients). GVHD was graded according to published criteria. 19, 20 Engraftment was judged complete on the third day when the neutrophil count was X0.5 Â 10 9 /L.
Transplant procedures
The transplant procedures have been previously described. 21 Myeloablative conditioning principally consisted of CY alone or in combination with BU. In five cases, CY, BU and melphalan were administrated. One patient was treated with BU combined with treosulfan, and in another case CY in combination with etoposide was used. Reducedintensity conditioning consisted of fludarabine in combination with one or more of BU, CY, melphalan, thiotepa and treosulfan. T-cell depletion was performed in vivo with either antithymocyte globulin or alemtuzumab to patients undergoing mismatched or unrelated transplantation. CsA and MTX were the most frequently used GVHD prophylaxis, and patients developing acute GVHD were treated with corticosteroids.
PCR methods
All PCR analyses were performed at the accredited clinical virological laboratory at Karolinska University Hospital. The presence of AdV DNA was detected by a previously described quantitative real-time PCR method. 10 The sensitivity of the PCR was five copies/PCR based on AdV serotype 5. The sensitivity of the PCR for the other serotype or genotypes was not determined. However, AdV isolates belonging to groups A-F were tested to be positive with the PCR method. Samples that tested positive for AdV DNA were sent to the laboratory at Umea˚University, Sweden, for genotyping and confirmation of results. Results from detection of AdV were registered in the medical record and made accessible for clinicians.
Enzyme-linked immunosorbent spot (ELISPOT) assay
Culture plates (96-well polyvinylidene difluoride plates; Millipore Corp., Billerica, MA, USA) were pre-wet with 70% ethanol and coated (100 mL/well) with antihuman IFN-g mAb 1-D1K (Mabtech AB, Stockholm, Sweden) diluted to 15 mg/mL in sterile-filtered PBS 1 day before PBMC separation at 4 1C. PBMCs were isolated from heparinized peripheral blood samples by LymphoPrep gradient (Nycomed, Oslo, Norway). After washing twice in tissue culture medium, cells were suspended at a concentration of 5 Â 10 6 /mL. PBMCs (5 Â 10 5 /well) plus 10 mg/mL of adenolysate or 10 mg/mL of negative control were incubated overnight at 371C in 5% CO 2 (the adenolysate and the negative control were gifts from Dr Tobias Feuchtinger, Tu¨bingen, Germany). As a positive control, cells were stimulated with PHA (Sigma-Aldrich, St Louis, MO, USA) at 1 mg/mL in a identical manner except for two wells left without stimulation. For detection, biotinylated mAb (7-B6-1-biotin) (Mabtech AB) and then streptavidin-alkaline phosphatase (Mabtech AB) was diluted in filtered PBS with FBS (0.5%) to a concentration of 1 mg/ mL and then added to each well. After washing, the cells were developed by adding 100 mL of colorimetric substrate (BCIP/NBT-plus; Mabtech AB) per well and, finally, counted in an Elispot reader. 22 Samples were considered positive when the mean number of spots in the wells stimulated with the adenolysate minus the number of spots in wells stimulated with the negative control was X20 spots.
Statistics
A multiple logistic regression model was created for multivariate analysis of risk factors for AdV infection. A P-value ofp0.05 was considered significant. The software used was Statistica version 8.0 for Windows. patients who died before the follow-up study ended 1 year after HSCT, a median of 11 samples (range 2-15) was analyzed with a median of 84 days (range between the first and the last sample. For all patients, a median of 11 samples (range 2-19) was collected weekly for AdV PCR direct after HSCT. The patient characteristics are presented in Table 1 . A total of five of 97 (5%) patients, three children and two adults, had at least one sample that tested positive for AdV DNA in peripheral blood, although none of them had clinical evidence of AdV disease. No patient was treated with AdV antiviral drugs. Patients 1-4 had only one or two samples that were positive for AdV DNA, and these were of low titers (o1000 copies/mL; Table 2 and Figure 1 ) that later cleared completely in three of the patients. However, patient 3 died two weeks after detection of AdV DNA, which was also found in both the intestine and kidney at autopsy. Nevertheless, GVHD and possibly BK virus infection were considered the most likely causes of death. Patients 1, 2 and 4 had no AdV-positive results registered from other body fluids. Patient 5 had detectable AdV DNA for a period of 3 months, consisting of two peaks divided by a short interval when no AdV DNA was detectable. The maximum viral load was 9000 copies/mL. The patient was AdV positive in feces in one out of five samples collected during the infection. In this case antiviral treatment against AdV was considered but avoided because of lack of symptoms. However, if the copies had risen even higher, the clinicians would have started the treatment even with the absence of symptoms. During the whole period of AdV viremia the strategy was to closely monitor the titer and symptoms. Subsequent genotyping of the viruses that caused low titers of infection identified three of them as AdV types 2, 3 and 31. The virus that infected patient 5 was identified as type 1 in both peaks. Of the patients with no AdV DNA detected in blood only three had clinical samples with detectable AdV DNA: two in colon biopsies and one in feces.
Results

Study population and the presence of AdV
The number of days after HSCT until detection of AdV DNA was 12, 60 and 90 in the three children. For the two adults, AdV infection was detected on days 82 and 118. Four (27%) of the patients transplanted for myelodysplastic syndrome (MDS) had AdV infection compared with one (1%) of the patients transplanted for other diagnosis (Wald test: odds ratio 56.2; confidence interval 3.6-876). Furthermore, being transplanted with a BM graft was overrepresented in the AdV-positive group (Wald test: odds ratio 15.7; confidence interval 1.2-204). The factors with no effect on the risk for AdV infection were type of conditioning (myeloablative conditioning or reduced-in- Adenovirus in SCT recipients L Öhrmalm et al tensity conditioning), in vivo T-cell depletion (antithymocyte globulin or alemtuzumab), fractioned TBI, the use of mismatched or unrelated donors and GVHD occurring before AdV infection.
Measurement of AdV-specific T-cell response
A total of 12 randomly selected adults from our study population were assayed at three time points, 4, 8 and 12 weeks after transplantation, and four patients were assayed at one time only. Seven (58%) of the patients were positive (spot-forming units X20) on at least one of the three time points (data not shown). None of the 12 patients had detectable AdV DNA during the period of measurement of AdV-specific T-cell response. Five out of six patients with unrelated donors received either antithymocyte globulin or alemtuzumab during conditioning and 8/11 (72.7%) samples were ELISPOT positive, whereas in the other six patients with sibling donors, only 5/15 (33.3%) samples were positive. In two patients who received alemtuzumab at 1 and 3 days before transplantation, respectively, one was positive at week 4 whereas both were positive at 8 and 12 weeks after SCT.
Discussion
In this study we present one of the largest prospective studies undertaken as yet to identify AdV DNA in the peripheral blood of HSCT recipients. Samples were collected from these patients in parallel with routine CMV surveillance by PCR. During a follow-up period of 1 year, we found that although 5% of the patients had an AdV infection, titers were low in all but one, and none had clinically overt AdV disease. Interestingly, even this relatively small number of AdV-infected patients allowed us to define two independent risk factors for acquiring AdV infection in this setting: MDS as the indication for transplantation, and BM as a source of stem cells.
The reported incidence of AdV infection after allogeneic HSCT has increased during the past decades. 3, 5 The probable cause is an increase in the number of high-risk patients undergoing HSCT. Subsequently, newfound awareness of AdV may have led to more intense surveillance strategies reinforced by the application of new sensitive methods for molecular diagnosis. Several risk factors for AdV infection have been identified with different levels of effect on incidence: younger age, 5, [23] [24] [25] usage of T cell-depleted grafts, 13, 26, 27 grafts from an unrelated donor, 23 GVHD or its therapy 28 and a slow lymphocyte recovery. 13, 27 In particular, transplantation of CD34 þ selected grafts were related to an increased incidence of AdV infection. 29 Independently of risk factors, the number of specimens sampled may account for reported variations in the incidence of AdV infection. In this study, we found a relatively low frequency of AdV-infected Table 2 Characteristics and outcomes of adult and pediatric HSCT patients with AdV infection Time points for onset of GVHD, engraftment and death are plotted.
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L Öhrmalm et al patients, presumably because of the large number of adults included, the absence of T cell-depleted and CD34 þ selected grafts, and the fact that only peripheral blood was analyzed. Furthermore, the median age of the children was rather high and only five children below 5 years of age were included. In addition, the treatment of CMV with ganciclovir may have influenced the number of patients with AdV DNA. 24 The absence of data on lymphocyte recovery, which is known to have a strong effect on the outcome, 13, 27 is a weakness of this study. Out of five AdVpositive patients, four had one or two positive samples, all with low titers, and none of the patients had compatible clinical symptoms. However, as AdV is a pathological finding in plasma, we have defined these findings as 'infection'. Four different serotypes of AdV from three different species were detected: 1 and 2 (species C), 3 (species B) and 31 (species A). The positive cases were few, which could explain the absence of other common serotypes.
The objective of this analysis was to determine whether screening for AdV DNA in peripheral blood is advisable along with the routine screening for CMV. The issues to consider, in addition to clinical relevance, are the extra blood sampling needed especially in small children and the cost for the PCR. Our study would not support routine AdV screening in an unselected population of patients undergoing HSCT. However, taking results from other large prospective studies 13, 26, 30 into consideration, together with the practical and economical aspects of the sampling and laboratory work, we are not dismissing the idea of AdV screening. Detection of AdV DNA in peripheral blood and especially rapid increase in the viral load is associated with progression to disseminated AdV disease. 9, 11, 26, 31 It would therefore be logical to identify what group of patients to screen and in what period after HSCT. As adults seem to get their AdV infection later in the post transplantation period, and the risk for AdV disease seems to be low, 25 a sampling schedule parallel to CMV screening may not be adequate. In contrast, children often get their AdV infection within 30 days after transplantation, 25 and treatment with cidofovir in this patient group has in most published reports been shown to be efficient and often without unacceptable side effects. 32 Thus, weekly screening of pediatric HSCT recipients in the direct post-HSCT period may be motivated.
Our ELISPOT data showed that more than half of randomly selected adults had T-cell immune responses against AdV on at least one time point during the first 3 months. Although not addressed in our study, the presence of AdV-specific T cells of a donor origin may contribute to prevention of AdV infection early after SCT. Alemtuzumab is described in several reports, both in pediatrics and in adults, as a high risk factor for AdV infection due to delayed lymphocyte recovery, which may extend to 490 days after transplantation. 13, [33] [34] [35] Only two of the patients measured for the presence of AdV-specific T cells received alemtuzumab, and both had detectable AdV-specific T cells.
Although the number of AdV-positive cases was low, we conclude that AdV infection is more commonly detected in patients with MDS as an indication for HSCT. In addition, using BM as the hematopoietic stem cell origin was found to be a risk factor for AdV acquisition. Screening for AdV DNA in peripheral blood in this patient group, with this setting of risk factors, did not affect the outcome; screening may have a better effect on other groups with other risk factors.
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